Raleigh Capital Management’s GSK GSK Stock Holding History

Raleigh Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$458	Sell	9 -3,561	-100%	-$188K	﹤0.01%	471
2026 Q1	$197K	Sell	3,570 -26,529	-88%	-$1.44M	0.07%	201
2025 Q4	$1.48M	Sell	30,099 -5,240	-15%	-$244K	0.54%	57
2025 Q3	$1.53M	Buy	35,339 +351	+1%	+$13.7K	0.58%	59
2025 Q2	$1.34M	Buy	+34,988	New	+$1.34M	0.56%	56
2025 Q1	–	Sell	-48	Closed	-$1.62K	–	760
2024 Q4	$1.62K	Hold	48	–	–	﹤0.01%	854
2024 Q3	$1.96K	Hold	48	–	–	﹤0.01%	819
2024 Q2	$1.85K	Hold	48	–	–	﹤0.01%	792
2024 Q1	$2.06K	Sell	48 -16	-25%	-$660	﹤0.01%	763
2023 Q4	$2.35K	Hold	64	–	–	﹤0.01%	849
2023 Q3	$2.3K	Buy	64 +16	+33%	+$568	﹤0.01%	765
2023 Q2	$1.71K	Buy	+48	New	+$1.72K	﹤0.01%	742
2022 Q4	–	Sell	-174	Closed	-$5K	–	821
2022 Q3	$5K	Sell	174 -112	-39%	-$4.25K	﹤0.01%	482
2022 Q2	$16K	Hold	286	–	–	0.01%	307
2022 Q1	$16K	Sell	286 -8	-3%	-$435	0.01%	311
2021 Q4	$16K	Buy	+294	New	+$15.3K	0.02%	173

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Raleigh Capital Management's GSK Position: Q2 2026 in Review

Raleigh Capital Management reduced its GSK (GSK) stake by 100% in Q2 2026, selling an estimated $188K and leaving 9 shares worth $458. The position accounts for ﹤0.01% of the portfolio, ranked #471.

Raleigh Capital Management first reported a position in GSK in Q4 2021 and has held it in 16 quarters since. The position peaked at $1.53M in Q3 2025. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Raleigh Capital Management held 9 shares of GSK worth $458 as of Q2 2026.
Raleigh Capital Management sold 3,561 GSK shares in Q2 2026, an estimated $188K.
GSK made up ﹤0.01% of Raleigh Capital Management's portfolio in Q2 2026, its #471 holding.
Raleigh Capital Management first reported a position in GSK in Q4 2021 and has held it in 16 quarters since.
Raleigh Capital Management's GSK position peaked at $1.53M in Q3 2025.
1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.